A global phase II, single-arm, open-label study to determine the efficacy of midostaurin in patients with aggressive systemic mastocytosis (ASM) or mast cell leukemia (MCL) with or without an associated hematologic clonal nonmast cell lineage disease (AHNMD).

被引：0
|
作者：
Gotlib, J. R.
Kluin-Nelemans, H.
Mauro, M. J.
Hermine, O.
Hexner, E. O.
Lipton, J. H.
Awan, F. T.
Nikolova, Z. G.
Gross, S. H.
Dutreix, C.
Dharan, B.
George, T.
Horny, P.
Akin, C.
Hartmann, K.
Valent, P.
Reiter, A.
机构：
[1] Stanford Univ, Stanford, CA 94305 USA
[2] Univ Med Ctr Groningen, NL-9713 AV Groningen, Netherlands
[3] Oregon Hlth & Sci Univ, Knight Canc Inst, Portland, OR 97201 USA
[4] Hop Necker Enfants Malad, Paris, France
[5] Univ Penn, Philadelphia, PA 19104 USA
[6] Princess Margaret Hosp, Toronto, ON M4X 1K9, Canada
[7] Georgia Hlth Sci Univ, Augusta, GA USA
[8] Novartis Pharmaceut AG, Basel, Switzerland
[9] Novartis Pharma AG, Basel, Switzerland
[10] Novartis Pharmaceut, Hanover, NH USA
[11] Inst Pathol, Ansbach, Germany
[12] Brigham & Womens Hosp, Boston, MA 02115 USA
[13] Univ Cologne, D-50931 Cologne, Germany
[14] Med Univ Vienna, Vienna, Austria
[15] Univ Med Mannheim, Mannheim, Germany
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2011年 / 29卷 / 15期
关键词：
D O I：
10.1200/jco.2011.29.15_suppl.tps200
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
TPS200
引用
收藏
页数：1
相关论文
共 50 条
  • [1] The classification of systemic mastocytosis should include mast cell leukemia (MCL) and systemic mastocytosis with a clonal hematologic non-mast cell lineage disease (SM-AHNMD)
    Valent, Peter
    Arock, Michel
    Akin, Cem
    Sperr, Wolfgang R.
    Reiter, Andreas
    Sotlar, Karl
    Hartmann, Karin
    George, Tracy I.
    Brockow, Knut
    Kluin-Nelemans, Hanneke C.
    Gotlib, Jason
    Metcalfe, Dean D.
    Horny, Hans-Peter
    BLOOD, 2010, 116 (05) : 850 - 851
  • [2] Intense FDG uptake in Aggressive Systemic Mastocytosis (ASM) without Associated clonal Haematological Non-Mast-cell lineage Disease (AHNMD): Unusual FDG PET/CT presentation
    Zaman, M.
    Fatima, N.
    Zaman, A.
    Zaman, S.
    Zaman, U.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2022, 49 (SUPPL 1) : S680 - S680
  • [3] Efficacy of Avapritinib in Patients with Advanced Systemic Mastocytosis: Hematologic and Bone Marrow Responses from the Phase 2 Open-Label, Single-Arm, Pathfinder Study
    George, Tracy I.
    Karner, Kristin H.
    Moser, Karen A.
    Rets, Anton
    Fredericks, Michelle
    Reiter, Andreas
    Radia, Deepti H.
    Deininger, Michael W.
    Lin, Hui-Min
    Sen, Jayita
    Gotlib, Jason
    Dimitrijevic, Sasa
    Deangelo, Daniel J.
    BLOOD, 2021, 138
  • [4] Cabozantinib in advanced renal cell carcinoma: A phase II, open-label, single-arm study of Japanese patients
    Tomita, Yoshihiko
    Tatsugami, Katsunori
    Nakaigawa, Noboru
    Osawa, Takahiro
    Oya, Mototsugu
    Kanayama, Hiroomi
    Kondoh, Chihiro Nakayama
    Sassa, Naoto
    Nishimura, Kazuo
    Nozawa, Masahiro
    Masumori, Naoya
    Miyoshi, Yasuhide
    Kuroda, Shingo
    Tanaka, Shingo
    Kimura, Akiko
    Tamada, Satoshi
    INTERNATIONAL JOURNAL OF UROLOGY, 2020, 27 (11) : 952 - 959
  • [5] EFFICACY AND SAFETY OF AVAPRITINIB IN PATIENTS WITH ADVANCED SYSTEMIC MASTOCYTOSIS: INTERIM RESULTS FROM THE OPEN-LABEL, SINGLE-ARM, PHASE 2 PATHFINDER STUDY
    Vannucchi, A. M.
    DeAngelo, D. J.
    Reiter, A.
    Radia, D.
    Deininger, M. W.
    George, T. I.
    Panse, J.
    Jentzsch, M.
    Alvarez-Twose, I.
    Mital, A.
    Hermine, O.
    Dybedal, I.
    Hexner, E. O.
    Hicks, L. K.
    Span, L.
    Mesa, R.
    Bose, P.
    Pettit, K. M.
    Heaney, M. L.
    Oh, S.
    Sen, J.
    Lin, H-M.
    Mar, B. G.
    Gotlib, J.
    HAEMATOLOGICA, 2021, 106 (10) : 2 - 2
  • [6] Phase II Open-Label, Single-Arm Trial to Investigate the Efficacy and Safety of Topical Remetinostat Gel in Patients with Basal Cell Carcinoma
    Kilgour, James M.
    Shah, Aatman
    Urman, Nicole M.
    Eichstadt, Shaundra
    Do, Hanh N.
    Bailey, Irene
    Mirza, Amar
    Li, Shufeng
    Oro, Anthony E.
    Aasi, Sumaira Z.
    Sarin, Kavita Y.
    CLINICAL CANCER RESEARCH, 2021, 27 (17) : 4717 - 4725
  • [7] A PROSPECTIVE PHASE II, OPEN-LABEL, SINGLE-ARM, MULTICENTER STUDY TO ASSESS THE EFFICACY AND SAFETY OF SEG101 (CRIZANLIZUMAB) IN SICKLE CELL DISEASE PATIENTS WITH PRIAPISM (SPARTAN)
    Burnett, A.
    El Rassi, F.
    Darbari, D.
    Paulose, J.
    Laine, D.
    Purkayastha, D.
    Kato, G.
    JOURNAL OF SEXUAL MEDICINE, 2020, 17 (01): : S43 - S43
  • [8] A Prospective Phase II, Open-Label, Single-Arm, Multicenter Study to Assess the Efficacy and Safety of SEG101 (Crizanlizumab) in Sickle Cell Disease Patients with Priapism (SPARTAN)
    El Rassi, Fuad A.
    Darbari, Deepika S.
    Burnett, Arthur
    Paulose, Jincy
    Laine, Dramane I.
    Purkayastha, Das
    Kato, Gregory J.
    BLOOD, 2019, 134
  • [9] Apatinib in Patients with Relapsed or Refractory Diffuse Large B Cell Lymphoma: A Phase II, Open-Label, Single-Arm, Prospective Study
    Ma, Xinran
    Li, Ling
    Zhang, Lei
    Fu, Xiaorui
    Li, Xin
    Wang, Xinhua
    Wu, Jingjing
    Sun, Zhenchang
    Zhang, Xudong
    Feng, Xiaoyan
    Chang, Yu
    Zhou, Zhiyuan
    Nan, Feifei
    Zhang, Jieming
    Li, Zhaoming
    Zhang, Mingzhi
    DRUG DESIGN DEVELOPMENT AND THERAPY, 2020, 14 : 275 - 284
  • [10] Efficacy and safety of JMT103 in patients with giant cell tumor of bone: A multicenter, single-arm, open-label, phase Ib/II study.
    Niu, Xiaohui
    Wei, Feng
    Tu, Chongqi
    Huang, Gang
    Bi, Wenzhi
    Li, Jianmin
    Yao, Weitao
    Zhang, Xiaojing
    Shen, Jingnan
    Zhang, Guochuan
    Yan, Wangjun
    Yang, Jilong
    Lin, Jianhua
    Ye, Zhaoming
    Wang, Dong
    Guo, Zheng
    Tong, Zhichao
    Zhou, Yuhong
    Xu, Hairong
    Li, Tao
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
12345